Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI is acquiring cancer-monitoring firm Personalis for $1.5 billion, though market reaction has seen shares for both companies dive.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 8.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: GuruFocus · Law360 · HLTH · Seeking Alpha · qz.com · Fierce Biotech · Business Wire · Barron's.
How this dossier is built: methodology · AI policy · corrections.
📍 How it ended
Tempus AI acquired cancer-monitoring firm Personalis in a $1.5 billion stock deal to expand its precision oncology platform. Following the announcement, shares for both companies sank.
Epilogue added 43d ago, after coverage quieted.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Tempus AI has entered an agreement to acquire Personalis in a $1.5 billion stock deal. The acquisition is intended to expand Tempus AI's precision oncology platform by more tightly integrating molecular residual disease (MRD) capabilities.
Coverage from Reuters, Barron's, and Investor's Business Daily emphasizes the immediate market reaction, noting that shares for both companies sank following the announcement. Technical and legal details reported by Law360 identify Latham and Cooley as the firms steering the deal.
Future developments center on the integration of Personalis's cancer genomics and monitoring tools into the AI-enabled platform provided by Tempus AI.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 43d ago.
Coverage (10)
- Tempus AI (TEM) to Acquire Personalis (PSNL) for $1.5B in Strate GuruFocus · 45d ago
- Latham, Cooley Steer $1.5B Tempus Cancer Testing Deal Law360 · 45d ago
- Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform HLTH · 45d ago
- Personalis: Tempus Bought The Best Part Of The Story (NASDAQ:PSNL) Seeking Alpha · 45d ago
- Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal qz.com · 45d ago
- Tempus buys out cancer genomics partner Personalis in $1.5 billion deal Fierce Biotech · 45d ago
- Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Business Wire · 45d ago
- Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink Barron's · 45d ago
- Tempus to buy cancer test maker Personalis for $1.5 billion Reuters · 45d ago
- Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive Investor's Business Daily · 45d ago
The obvious questions
How much is Tempus AI paying for Personalis?
The acquisition is valued at $1.5 billion.
What is the primary goal of the acquisition?
Tempus AI aims to expand its precision oncology platform and integrate molecular residual disease (MRD) monitoring.
How did the stock market respond to the news?
According to Barron's and Investor's Business Daily, shares for both Tempus AI and Personalis sank.
Topics
Related trends
ONEOK to Buy Brazos Midstream’s Permian Assets for $4.43 Billion
ONEOK shifts away from winding down mergers and acquisitions to pursue a $4.43 billion Permian Basin asset purchase.
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.
Open-weight AI companies are the Valley’s hottest acquisition targets
Nvidia's interest in Hugging Face signals a new wave of acquisitions in the open-weight AI sector.
Cancer is quantum: Studies show cancer cells may occupy limited, shared states like quantized energy levels
Recent studies suggest cancer cells may behave like quantum systems, occupying limited, shared states.
Shell draws Exxon interest in $8bn US chemical assets sale
Exxon and LyondellBasell are competing to buy Shell's US chemical assets, valued at up to $8 billion.
Hugging Face has been fielding M&A interest for a deal worth at least $13 billion
Hugging Face is exploring a potential sale valued at $13 billion, sparking interest in the AI sector.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.